Research Education
PerformanceLabsUK supplies third party tested research reference materials for in vitro laboratory and scientific research use only, not for human or veterinary use.
Tirzepatide is a synthetic peptide studied in metabolic receptor pharmacology research as a dual receptor agonist. It acts on two incretin receptors, which is what sets it apart in the literature from single-receptor GLP-1 agonists. This page gives a general, research-framed overview of what published literature examines, for research reference purposes only.
Tirzepatide (development code LY3298176) is a 39 amino acid linear peptide. Its sequence is based on native GIP (glucose-dependent insulinotropic polypeptide), modified so that it also activates the GLP-1 receptor. A C20 fatty diacid is attached through a linker, which supports binding to albumin. Published pharmacokinetic studies report a half-life of around five days, much longer than the native hormones it is modelled on.
Research on Tirzepatide sits within incretin biology, the study of gut-derived hormones and their receptors. Laboratory and preclinical work has examined its activity at the GIP and GLP-1 receptors, its signalling profile, and how dual receptor activation compares with activating either receptor alone. The molecule was first characterised by Coskun and colleagues in Molecular Metabolism in 2018.
Human clinical research was carried out by its developer through large phase 3 programmes, including SURPASS and SURMOUNT, which examined glycaemic and body weight endpoints. These programmes used products manufactured under medicinal controls and are referenced here for research context only.
Tirzepatide does not act on its two receptors equally. Willard and colleagues (JCI Insight, 2020) described it as an imbalanced agonist, with greater relative activity at the GIP receptor than at the GLP-1 receptor. They also reported biased signalling at the GLP-1 receptor: it favours cAMP generation over beta-arrestin recruitment, which is linked in the literature to differences in receptor internalisation. This profile is one of the most studied aspects of the molecule.
| Class | Receptor targets studied | Example |
|---|---|---|
| Single agonist | GLP-1 | Semaglutide |
| Dual agonist | GIP, GLP-1 | Tirzepatide |
| Triple agonist | GIP, GLP-1, glucagon | Retatrutide |
For a direct comparison with the triple agonist, see Retatrutide vs Tirzepatide. The wider class is covered in GLP-1, GIP and glucagon receptor agonist research.
Tirzepatide is listed as a research reference material, supplied for in vitro laboratory investigation only, with a batch-specific Certificate of Analysis.
You must be 18 or over to enter this site.
WARNING: This website contains age-restricted content.
Join the list for new compound drops, batch COAs, and plain English research notes. Your code arrives straight away.
All products are supplied strictly for in vitro laboratory research use. Not for human or veterinary consumption.
